PYPei Yang

Pei Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pei Yang has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Zhiyan Sun

    Department of Gamma Knife, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    8 shared publications
  • Rui Tao

    Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    7 shared publications
  • Xiaoyan Zhao

    School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing, China

    7 shared publications
  • Minghui Du

    Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    6 shared publications
  • Xianhao Wu

    School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing, China

    6 shared publications
  • Zhaohui Zhang

    School of Automation and Electrical Engineering, University of Science and Technology Beijing, Beijing, China

    6 shared publications

Latest Publications

  • Open Access

    Laser Interstitial Thermal Therapy Followed by Ultra Early Temozolomide for First Recurrent IDH Wild Type Glioblastoma: A Comparative Cohort Study With Prospective Enrolment and Retrospective Controls

    by Yutao Zhang, Xuzhe Zhao, Pei Yang, Kai Wang, Yong-Gang Wang, Yinyan Wang, Xiaohui Ren, Dabiao Zhou

    Background: Evidence for laser interstitial thermal therapy (LITT) followed by ultra-early temozolomide at first recurrence of IDH-wild-type glioblastoma is limited. We assessed survival relative to nonsurgical management while accounting for measured treatment-selection differences. Methods: This single-centre comparative cohort study combined a prospective phase II LITT cohort (NCT05663125) with retrospective controls at Beijing Tiantan Hospital, China, during 2018–2024. Eligible patients were aged 18–75 years, had a first recurrence, and had Karnofsky Performance Status of at least 60. The complete-case cohort included 90 patients: ten receiving LITT, 43 surgery, and 37 nonsurgical management. Temozolomide began on postoperative day 2 after LITT. The primary overall survival comparison used LITT-focused propensity-score weighting targeting the average treatment effect on the treated. Secondary surgery analyses used overlap weighting; subgroup and PET/MR analyses were exploratory. Confidence intervals for 12-month restricted mean survival time differences were estimated with 10 000 stratified nonparametric bootstrap resamples, repeating propensity-score weighting within each resample. Findings: LITT plus ultra-early temozolomide was associated with longer survival than nonsurgical management (hazard ratio 0·31 [95% CI 0·13–0·77]; p=0·012). Twelve-month restricted mean survival was 305·95 versus 221·00 days, a difference of 84·95 days (percentile bootstrap 95% CI 4·67–173·28). The secondary surgery comparison yielded a hazard ratio of 0·39 (0·19–0·80; p=0·010) and a 12-month restricted mean survival difference of 54·54 days (−25·68 to 128·79). Insufficient common support precluded a reliable direct LITT–surgery comparison. PET/MR coverage was assessable in nine patients, with no statistically significant metric. Interpretation: LITT followed by ultra-early temozolomide was associated with longer survival in patients resembling the LITT cohort. The small, non-randomised study cannot establish causality or separate the contributions of LITT and temozolomide timing. Prospective comparative validation is needed.

  • Open Access

    Terahertz-based prognostic framework for glioma: from spectral features to patient-level prognostic assessment

    by Minghui Du, Rui Tao, Zhiyan Sun, Peiyuan Sun, Xianhao Wu, Yubo Wu, Tianyi Bi, Zhaohui Zhang, Xiaoyan Zhao, Dabiao Zhou, et al.

  • Open Access

    Low-Cost Self-Driven Liquid Biosensor Based on Metamaterials for Glioblastoma-Related Sample Detection

    by Kanglong Chen, Minghui Du, Peiyuan Sun, Pei Yang, Xiaojun Wu

    A self-driven terahertz metamaterial liquid biosensor composed of channel-structured metamaterials and a quartz microcavity is proposed for glioblastoma sample detection. The device transports liquid samples via capillary force. The permittivity (εeff) of liquid suspensions is comprehensively analyzed to provide theoretical support for the detection. For suspensions with the same contents, εeff decreases with increasing concentration, while under the same concentration condition, εeff decreases as particle size grows. An electric dipole resonance is excited at ~1.54 THz with theoretical sensitivity ≥ 242 GHz/RIU (where RIU denotes refractive index unit). For the same type of cell discrimination, the frequencies of the biosensor’s feature peaks shift from ~1.14, ~1.18, and ~1.20 THz with the rise in cell concentration of glioblastoma stem cell (GSC) suspension from 4 × 105, 6 × 105 to 8 × 105 cells/mL, respectively. In addition, the GSC, U87 and U251—whose average diameters increase in that order—tested at the same concentration of 4 × 105 cells/mL lead to feature peak shifts from ~1.14, ~1.17, and ~1.20 THz. Clear THz differences exist between healthy and patient serum, with peaks at 1.18 and 1.19 THz. The sensor effectively distinguishes cell suspensions but has limited serum discrimination capacity. The sensor retains cell morphology, requires little pretreatment, and is low-cost and fast for rapid glioblastoma clinical screening.

  • Open Access

    Prediction of TP53 Mutation Status in Glioma Based on Terahertz Spectral Data and DA-RMCNet Model

    by Tianyi Bi, Yubo Wu, Minghui Du, Rui Tao, Yuan Yuan, Xianhao Wu, Yuehan Yang, Yu Zhang, Tianyao Zhang, Hao Zhang, et al.

    Glioma is the primary malignant tumor of the central nervous system and has a high mortality rate. TP53 is an important molecular marker in glioma, and its mutational status is closely associated with tumor malignancy and patient prognosis. To address the limitations of traditional molecular detection methods, such as long turnaround times, complex procedures, and difficulty in meeting intraoperative rapid diagnosis requirements, this paper proposes a TP53 mutation prediction method for glioma based on terahertz spectral data and a dual-attention residual multi-scale convolutional network (DA-RMCNet). Firstly, the collected terahertz absorption spectra of glioma tissues are preprocessed. Subsequently, a residual multi-scale convolutional network integrating a frequency attention mechanism and an SE (Squeeze-and-Excitation) channel attention mechanism is constructed to achieve synergistic enhancement of key spectral bands and important feature channels as well as multi-scale spectral feature extraction. Experimental results demonstrated that DA-RMCNet achieved a classification accuracy of 0.8636 and an AUC value of 0.9350 in the TP53 mutation prediction task, it is superior to traditional machine learning models.The results indicated that terahertz time-domain spectroscopy combined with deep learning methods were enable rapid prediction of TP53 mutation status in glioma, providing a technical approach for intraoperative molecular pathological diagnosis of glioma.

  • Open Access

    Heat shock proteins related signature characterizes immune status and predicts prognosis of gliomas

    by Zhiyan Sun, Haibin Wan, Minghui Du, Yiding Guo, Rui Tao, Xuzhe Zhao, Yutao Zhang, Pei Yang, Dabiao Zhou

    Glioma classification is crucial for effective diagnosis and treatment. Heat Shock Proteins (HSPs) have been associated with tumor development and progression. In this study, we established a prognostic model for glioma based on Heat Shock Proteins-associated genes (HSPGs). Using the Cancer Genome Atlas (TCGA) cohorts and the Chinese Glioma Genome Atlas (CGGA), we identified a signature of 4 HSPGs as an independent prognostic factor for glioma. The risk model demonstrated excellent performance in both training and validation sets. Additionally, we developed a nomogram incorporating clinical parameters and the HSPGs signature to enhance prognostic prediction. Immunoenrichment analysis revealed a correlation between the risk score and the immunosuppressive status of glioma. In the functional assays, HSPA5 was identified as a key participant in several critical biological processes associated with glioma. Silencing HSPA5 expression may lead to the inhibition of glioma cell proliferation, migration, invasion and resistance to apoptosis. These findings present a novel classification for glioma prognosis with enhanced accuracy and offer valuable insights into the potential use of HSPGs as prognostic indicators for gliomas.

  • Open Access

    Rapid diagnosis of TERT promoter mutation using Terahertz absorption spectroscopy in glioblastoma

    by Zhiyan Sun, Minghui Du, Xianhao Wu, Rui Tao, Peiyuan Sun, Shaowen Zheng, Zhaohui Zhang, Dabiao Zhou, Xiaoyan Zhao, Pei Yang

    Glioblastoma (GBM) is a highly aggressive brain tumor with poor outcomes and limited treatment options. The telomerase reverse transcriptase (TERT) promoter mutation, one of the key biomarkers in GBM, is linked to tumor progression and prognosis. This study employed terahertz time-domain spectroscopy (THz-TDS) to analyze frozen GBM tissue sections, extracting six spectral features: absorption coefficient, dielectric loss factor, dielectric constant, extinction coefficient, refractive index, and dielectric loss tangent. LASSO regression was employed for feature selection, and then principal component analysis (PCA) was applied to minimize inter-feature correlations. A Random Forest classifier built on these features successfully predicted TERT mutation status, achieving an area under the receiver operating characteristic curve (AUC) of 0.908 in the validation set. Our findings demonstrate that THz spectroscopy, coupled with machine learning, can identify molecular differences associated with TERT mutations, supporting its potential as a rapid, intraoperative diagnostic tool for personalized GBM treatment. This approach could enhance surgical decision-making and optimize patient outcomes through precise, real-time molecular diagnostics.


  • Design of a polarization-insensitive terahertz metamaterial biosensor for glioma tissue identification

    by Xianhao Wu, Minghui Du, Tianyao Zhang, Rui Tao, Yuan Yuan, Zhiyan Sun, Shaowen Zheng, Yuehan Yang, Yu Zhang, Can Cao, et al.

    There is an urgent need to develop label-free, accurate detection techniques for gliomas due to the high aggressiveness and heterogeneity of glioma tissues. In this study, a polarization-insensitive terahertz metamaterial biosensor based on a quadruple rotationally symmetric superunit is proposed to address the issues of insufficient sensitivity and polarization-dependent interference associated with conventional metamaterials in terahertz spectroscopy. The structural parameters were optimized through theoretical modeling and electromagnetic simulations, leading to the design of C4-symmetric metamaterials with stable responses over a wide incidence angle range. These metamaterials effectively mitigate signal distortion caused by the random orientation of metamaterial placement during experiments. The experiments were conducted using a terahertz frequency-domain spectroscopy system (THz-FDS) to detect isolated glioma tissues. The results demonstrate that the sensor maintains polarization insensitivity across the full 0-360° range, significantly enhancing the contrast in dielectric properties between tumor and normal tissues. Furthermore, its resonance frequency shift exhibits a strong correlation with tissue thickness, increasing up to 26 µm, after which it stabilizes and no longer exhibits significant changes. This study confirms that polarization-insensitive metamaterials can overcome existing imaging limitations, reduce operator-induced human errors, and provide a novel, non-invasive detection solution for intraoperative boundary delineation and pathological diagnosis of gliomas, with strong potential for clinical translation.


  • A predictive model for MGMT promoter methylation status in glioblastoma based on terahertz spectral data

    by Minghui Du, Xianhao Wu, Zhiyan Sun, Rui Tao, Peiyuan Sun, Shaowen Zheng, Zhaohui Zhang, Tianyao Zhang, Xiaoyan Zhao, Pei Yang


  • Open Access

    A reactive oxygen species-related signature predicts the prognosis and immunosuppressive microenvironment in gliomas

    by Xia Shan, Ruoyu Huang, Kuanyu Wang, Pei Yang

    Intracellular redox homeostasis is crucial for a series of physiological processes. Reactive oxygen species (ROS) play important roles in redox processes. ROS can maintain cell reproduction and survival at moderate levels while promoting the initiation and progression of tumors at high levels. Based on a comprehensive analysis of ROS-related gene expression profiles, we established a gene signature associated with ROS to explore its influence on prognosis and immune microenvironment in gliomas. The ROS-related gene expression profile dichotomized patients into two groups with different clinicopathological features and prognoses. A 19-gene ROS-related signature was used to robustly predict prognosis in both training and validation datasets. Functional analysis indicated an association between ROS levels and the immune microenvironment. The expression of immune checkpoints and M2-type markers was upregulated in the high-risk group, which suggested the immunosuppressive function of ROS. ROS-related signature is an independent prognostic factor in gliomas and could potentially exert immunosuppressive effects on the tumor microenvironment.


  • Ensemble learning prediction framework for EGFR amplification status of glioma based on terahertz spectral features

    by Xianhao Wu, Rui Tao, Zhiyan Sun, Tianyao Zhang, Xingyue Li, Yuan Yuan, Shaowen Zheng, Can Cao, Zhaohui Zhang, Xiaoyan Zhao, et al.